Merck: acquisition of Harpoon Therapeutics finalized
' We are delighted to welcome our Harpoon colleagues to Merck and look forward to working together to advance a new portfolio of T-cell activators, including MK-6070,' commented Dr. Dean Y. Li, President of Merck Research Laboratories.
MK-6070 is currently being evaluated in a phase 1/2 trial, as well as in combination with atezolizumab in selected small cell lung cancer (SCLC) patients.
Merck also points out that in March 2022, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to MK-6070 for the treatment of small cell lung cancer.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction